In an age when frown lines are optional but regulatory oversight is not, one might assume that the person wielding the Botox needle has more than a weekend’s worth of training. In much of the world, that assumption would be correct. But in Scotland and other jurisdictions with patchy oversight, a dose of filler can come with more risk than reward – sometimes with unfortunate consequences.
A tragic wake-up call
The tragic death of 33-year-old Alice Webb in September 2024 underscored the dangers of unregulated cosmetic procedures. Webb, a mother of five from Gloucestershire, died after undergoing a non-surgical Brazilian butt lift (BBL) at a studio in Gloucester. The procedure, involving the injection of fillers into the buttocks, was performed by an unlicensed practitioner. Webb’s death marked the first fatality from such a procedure in the UK and ignited urgent calls for stricter regulations.
Scotland’s non-surgical cosmetic sector has often been likened to the “wild west” due to its lack of stringent regulations. The absence of regulation means that individuals without medical training can administer such treatments, leading to significant risks. This regulatory gap has led to calls for standardized training and mandatory qualifications within the cosmetics industry.
In response to these concerns, the Scottish Government initiated a consultation process to explore the regulation and licensing of non-surgical cosmetic procedures. The aim is to ensure that all practitioners meet specific standards of training and practice, thereby safeguarding public health.
Regulating injectables across UK, Australia, and New Zealand
While Scotland has faced criticism for its lack of stringent oversight in non-surgical cosmetic procedures, other parts of the United Kingdom and Ireland exhibit a varied regulatory landscape. In England, the government announced plans in 2023 to introduce a mandatory licensing scheme for practitioners offering injectables and other non-surgical treatments, aiming to ensure consistent standards and enhance patient safety. Wales has signaled support for a similar regulatory approach, while Northern Ireland has initiated reviews but has yet to implement formal measures.
In contrast, Ireland enforces stricter regulations for certain procedures; botulinum toxin products are classified as prescription-only medicines, legally requiring administration by registered medical practitioners, such as doctors or dentists. However, the administration of dermal fillers in Ireland remains largely unregulated, allowing individuals without medical training to perform such procedures, raising significant safety concerns. This disparity underscores the pressing need for Scotland to advance its proposed licensing regime to align with broader efforts to standardize and enhance the safety of cosmetic treatments across the region.
Australia has implemented stringent regulations to oversee the cosmetic injectables industry. The requirement for practitioners to be registered health professionals, combined with guidelines on prescribing and administering injectables, reflects a commitment to patient safety. The TGA’s role in approving products ensures that only safe and effective injectables are used. Additionally, the prohibition of direct-to-consumer advertising of prescription medicines, including Botox, aims to prevent misleading promotions and protect consumers.
New Zealand’s approach falls between these two extremes. While the NZSCM provides training and recognition for cosmetic practitioners, the absence of mandatory regulations means that individuals with minimal training can administer cosmetic injectables. This regulatory gap permits individuals with limited or no formal medical training to perform cosmetic injectable procedures, raising significant safety concerns. For instance, reports have highlighted cases where dental hygienists and oral health therapists administer Botox without adequate training, leading to alarms about potential botched procedures and serious complications. Furthermore, the absence of mandatory regulations has led to situations where unqualified individuals perform cosmetic injections, sometimes resulting in adverse outcomes
Global disparities in cosmetic injectable regulations
The regulation of cosmetic injectables varies significantly across the globe, leading to inconsistent safety standards and practices. In countries like the United States, the Food and Drug Administration (FDA) oversees the approval and monitoring of cosmetic injectables, ensuring they meet stringent safety and efficacy standards before reaching the market. Conversely, some nations have minimal oversight, allowing individuals with limited or no medical training to administer these procedures, raising concerns about patient safety.
This regulatory patchwork has contributed to the rise of “medical tourism,” where individuals travel to countries with lax regulations to undergo more affordable treatments. While cost savings can be appealing, the lack of standardized regulations increases the risk of complications, including infections and unsatisfactory outcomes. The absence of international standardization underscores the need for global discussions on best practices and regulatory frameworks to protect consumers worldwide.
Tighter scrutiny for a growing industry
The cosmetic injectables industry continues to evolve, with increasing scrutiny from regulatory bodies. In Australia, recent incidents have prompted authorities to issue warnings about unregistered practitioners administering Botox injections, leading to severe health complications. For instance, three women in Sydney were hospitalized with suspected botulism after receiving anti-wrinkle injections from an unregistered practitioner.
In Queensland, new guidelines have been introduced requiring doctors to be present on-site for the administration of Botox and dermal fillers. This move aims to enhance patient safety but has also caused confusion among nurse-led clinics that previously operated under different protocols.
These developments indicate a global trend toward stricter regulation of the cosmetic injectables industry. As more countries recognize the need for comprehensive oversight, we can expect to see the implementation of standardized training requirements, mandatory qualifications, and robust monitoring systems. This shift aims to protect consumers and ensure that non-surgical cosmetic procedures are performed safely and effectively.
From consultation to change: What’s next
In Australia, the focus has shifted from introducing regulation to tightening enforcement. With a robust framework already in place, authorities are now confronting the practical challenges of ensuring compliance – particularly following high-profile cases of harm caused by unregistered practitioners. New rules in Queensland, requiring doctors to be physically present when Botox or fillers are administered, have sparked confusion in nurse-led clinics but underscore the commitment to patient safety.
New Zealand, by contrast, remains in regulatory limbo. While organisations like the New Zealand Society of Cosmetic Medicine offer voluntary training and credentialing, there is still no mandatory framework governing who can administer injectables. With the industry growing rapidly and concerns mounting, calls for legislative intervention are becoming louder.
In Scotland, the government’s consultation on licensing non-surgical cosmetic procedures closed in February and is now under review. A formal licensing scheme is expected to be introduced later in 2025. If successful, it could serve as a blueprint for broader reform across the UK – particularly in jurisdictions still lagging behind.
And back in Glasgow, the legacy of Alice Webb’s death continues to cast a long shadow over the aesthetics industry. A frown line may be easy to erase, but the damage from poorly administered injectables can run far deeper. Whether Scotland’s reforms arrive in time – and with enough teeth – may define how seriously the industry takes its duty of care.
